[1] INOZUME T. Recent clinical trials of tumor immunotherapy [J]. Nihon Rinsho Meneki Gakkai Kaishi,2013,36(3):134-138.
[2] COUZIN-FRANKEL J. Breakthrough of the year 2013 [J]. Cancer Immunother Sci,2013,342(6165):1432-1433.
[3] MCNUTT M. Cancer immunotherapy [J]. Science,2013,342(6165):1417.
[4] RAVAL R R,SHARABI A B,WALKER A J,et al.Tumor immunology and cancer immunotherapy:Summary of the 2013 SITC primer [J]. J Immunother Cancer,2014,2:14.
[5] ALY H A. Cancer therapy and vaccination [J]. J Immunol Methods,2012,382(1-2):1-23.
[6] YANG J,ZHANG Q,LI K,et al.Composite peptide-based vaccines for cancer immunotherapy (Review) [J]. Int J Mol Med, 2015,35(1):17-23.
[7] PEREZ S A,VON HOFE E,KALLINTERIS N L,et al. A new era in anticancer peptide vaccines [J]. Cancer,2010,116(9):2071-2080.
[8] YAMAGUCHI Y,YAMAUE H,OKUSAKA T,et al.Guidance for peptide vaccines for the treatment of cancer [J]. Cancer Sci,2014,105(7): 924-931.
[9] DENIES S,CICCHELERO L,VAN AUDENHOVE I,et al.Combination of interleukin-12 gene therapy,metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication [J]. J Controlled Release,2014,187:175-182.
[10] DEVAUD C,JOHN L B,WESTWOOD J A,et al.Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy [J]. Oncoimmunology, 2013,2(8):e25961.
[11] TAN Z,ZHOU J,CHEUNG A K,et al.Vaccine-elicited CD8+ T cells cure mesothelioma by overcoming tumor-induced immunosuppressive environment [J]. Cancer Res,2014,74(21):6010-6021.
[12] CRUZ L J,RUEDA F,CORDOBILLA B,et al.Targeting nanosystems to human DCs via Fc receptor as an effective strategy to deliver antigen for immunotherapy [J]. Molecular Pharm,2011,8(1):104-116.
[13] LIU S Y,WEI W,YUE H, et al. Nanoparticles-based multi-adjuvant whole cell tumor vaccine for cancer immunotherapy [J]. Biomaterials, 2013,34(33):8291-8300.
[14] MURAOKA D,HARADA N,HAYASHI T,et al.Nanogel-based immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity [J]. ACS Nano,2014,8(9):9209-9218.
[15] IRVINE D J,SWARTZ M A,SZETO G L. Engineering synthetic vaccines using cues from natural immunity [J]. Nat Mater,2013,12(11):978-990.
[16] IRVINE D J,HANSON M C,RAKHRA K, et al. Synthetic nanoparticles for vaccines and immunotherapy [J]. Chem Rev,2015,115(19):11109-11146.
[17] SWARTZ M A,HIROSUE S,HUBBELL J A. Engineering approaches to immunotherapy [J]. Sci Trans Med,2012,4(148): 148-149.
[18] FIFIS T,GAMVRELLIS A,CRIMEEN-IRWIN B, et al. Size-dependent immunogenicity: Therapeutic and protective properties of nano-vaccines against tumors [J]. J Immunol,2004,173(5): 3148-3154.
[19] XU Z,RAMISHETTI S,TSENG Y C,et al.Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis [J]. J Controlled Release,2013,172(1):259-265.
[20] XU Z,WANG Y,ZHANG L,et al.Nanoparticle-delivered transforming growth factor-beta siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment [J]. ACS Nano, 2014,8(4):3636-3645.
[21] CRUZ L J,ROSALIA R A,KLEINOVINK J W,et al.Targeting nanoparticles to CD40,DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: A comparative study [J]. J Controlled Release,2014,192: 209-218.
[22] KELLER S,WILSON J T,PATILEA G I, et al. Neutral polymer micelle carriers with pH-responsive,endosome-releasing activity modulate antigen trafficking to enhance CD8(+) T cell responses [J]. J Controlled Release,2014,191: 24-33.
[23] DE TITTA A,BALLESTER M,JULIER Z,et al. Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose [J]. Proc Natl Acad Sci USA,2013,110(49): 19902-19907.
[24] FOX C B,SIVANANTHAN S J,DUTHIE M S,et al. A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7 [J]. J Nanobiotechnol,2014,12: 17.
[25] CRUZ L J,RUEDA F,SIMON L,et al.Liposomes containing NYESO1/tetanus toxoid and adjuvant peptides targeted to human dendritic cells via the Fc receptor for cancer vaccines [J]. Nanomedicine (Lond), 2014,9(4):435-449.
[26] THOMANN J S,HEURTAULT B,WEIDNER S,et al.Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting [J]. Biomaterials, 2011,32(20):4574-4583.
[27] MANSOURIAN M,BADIEE A,JALALI S A, et al. Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN [J]. Immunol Lett,2014,162(1 Pt A):87-93.
[28] SHARIAT S,BADIEE A,JALALI S A,et al.P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer [J]. Cancer Lett,2014,355(1):54-60.
[29] ZHANG Z P,TONGCHUSAK S,MIZUKAMI Y,et al.Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery [J]. Biomaterials,2011,32(14):3666-3678.
[30] MA W,CHEN M,KAUSHAL S,et al.PLGA Nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses [J]. Int J Nanomed,2012,7:1475-1487.
[31] SALUJA S S,HANLON D J,SHARP F A,et al.Targeting human dendritic cells via DEC-205 using PLGA nanoparticles leads to enhanced cross-presentation of a melanoma-associated antigen [J]. Int J Nanomed, 2014,9:5231-5246.
[32] CAMPBELL D F,SAENZ R,BHARATI I S,et al.Enhanced anti-tumor immune responses and delay of tumor development in human epidermal growth factor receptor 2 mice immunized with an immunostimulatory peptide in poly(D,L-lactic-co-glycolic) acid nanoparticles [J]. Breast Cancer Res, 2015,17:48.
[33] MATSUO K,YOSHIKAWA T,ODA A,et al.Efficient generation of antigen-specific cellular immunity by vaccination with poly(gamma-glutamic acid) nanoparticles entrapping endoplasmic reticulum-targeted peptides [J]. Biochem Biophys Res Commun,2007,362(4):1069-1072.
[34] YAMAGUCHI S,TATSUMI T,TAKEHARA T,et al.EphA2-derived peptide vaccine with amphiphilic poly(gamma-glutamic acid) nanoparticles elicits an anti-tumor effect against mouse liver tumor [J]. Cancer Immunol Immunother,2010,59(5):759-767.
[35] TANG J,YIN R,TIAN Y,et al.A novel self-assembled nanoparticle vaccine with HIV-1 Tat(4)(9)(-)(5)(7)/HPV16 E7(4)(9)(-)(5)(7) fusion peptide and GM-CSF DNA elicits potent and prolonged CD8(+) T cell-dependent anti-tumor immunity in mice [J]. Vaccine,2012,30(6):1071-1082.
[36] LIU T Y,HUSSEIN W M,GIDDAM A K, et al. Polyacrylate-based delivery system for self-adjuvanting anticancer peptide vaccine [J]. J Med Chem, 2015,58(2):888-896.
[37] LIU T Y,HUSSEIN W M,JIA Z F,et al.Self-adjuvanting polymer-peptide conjugates as therapeutic vaccine candidates against cervical cancer [J]. Biomacromolecules,2013,14(8):2798-2806.
[38] YANG J,LI Z H,ZHOU J J,et al.Preparation and antitumor effects of nanovaccines with MAGE-3 peptides in transplanted gastric cancer in mice [J]. Chin J Cancer,2010,29(4):359-364.
[39] LIN A Y,LUNSFORD J,BEAR A S, et al. High-density sub-100-nm peptide-gold nanoparticle complexes improve vaccine presentation by dendritic cells in vitro [J]. Nanoscale Res Lett,2013,8(1):72.
[40] ALMEIDA J P,LIN A Y,FIGUEROA E R, et al. In vivo gold nanoparticle delivery of peptide vaccine induces anti-tumor immune response in prophylactic and therapeutic tumor models [J]. Small, 2015,11(12):1453-1459.
[41] SHI R,HONG L,WU D,et al.Enhanced immune response to gastric cancer specific antigen peptide by coencapsulation with CpG oligodeoxynucleotides in nanoemulsion [J]. Cancer Biol Ther,2005,4(2):218-224.
[42] AGUILAR F F,BARRANCO J J,FUENTES E B,et al.Very small size proteoliposomes (VSSP) and montanide combination enhance the humoral immuno response in a GnRH based vaccine directed to prostate cancer [J]. Vaccine,2012,30(46): 6595-6599.
[43] VASIEVICH E A,RAMISHETTI S,ZHANG Y,et al. Trp2 peptide vaccine adjuvanted with (R)-DOTAP inhibits tumor growth in an advanced melanoma model [J]. Mol Pharm,2012,9(46):261-268.